Simplified Asthma Inhalers

Clean the Sky - Positive Eco Trends & Breakthroughs

This Once-a-Day Inhaler Provides 24-Hour Relief

— January 23, 2015 — Lifestyle
A new once-a-day inhaler by the name of Relvar Ellipta will be available for asthma sufferers in Britain. The inhaler combines a daily dose of steroid, which is used to reduce inflammation in the airways, with a new type of long-lasting beta2 agonist, which focuses on dilation.

The product speaks to a need for simplicity, as studies show that many asthma patients find it difficult to manage two separate inhalers. The long-lasting drug will provide relief throughout the entire day, although some users may have to carry a blue inhaler for "immediate relief."

The drug is not limited to those with asthma however; it can also be used to combat a long list of respiratory illnesses, such as COPD.


Trend Themes

  1. Simplified Asthma Treatment — The development of a once-a-day inhaler for asthma sufferers addresses the need for simpler treatment options.
  2. Combination Inhalers — The combination of a steroid and a long-lasting beta2 agonist in a single inhaler offers convenience and better management of respiratory illnesses.
  3. Expanded Applications for Inhalers — The use of the new inhaler beyond asthma treatment opens up opportunities for treating various respiratory illnesses such as COPD.

Industry Implications

  1. Pharmaceuticals — The development and manufacturing of simplified inhalers provide opportunities for pharmaceutical companies to enhance asthma and respiratory illness treatments.
  2. Healthcare — The introduction of once-a-day inhalers in healthcare facilitates improved management of asthma and respiratory conditions, potentially leading to better patient outcomes.
  3. Medical Devices — The innovation in inhaler technology creates disruptive opportunities for medical device companies to create more efficient and user-friendly respiratory treatment devices.
2
Score
Popularity
Activity
Freshness